Thrivent Financial for Lutherans Buys 3,675 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Thrivent Financial for Lutherans raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 446.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,498 shares of the medical research company’s stock after acquiring an additional 3,675 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Bio-Rad Laboratories were worth $1,505,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Capital Advisors Ltd. LLC raised its holdings in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 62 shares during the period. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $32,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $51,000. Finally, Quarry LP acquired a new position in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $59,000. 65.24% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP James Barry sold 623 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 80.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of BIO opened at $340.53 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of -12.46 and a beta of 0.93. The stock has a fifty day moving average of $340.77 and a 200-day moving average of $317.76.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same period last year, the company earned $2.33 earnings per share. The business’s quarterly revenue was up 2.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of analyst reports. Royal Bank of Canada lifted their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Finally, Citigroup boosted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.